Effect of Individual Patient Characteristics and Treatment Choices on Reliever Medication Use in Moderate-Severe Asthma: A Poisson Analysis of Randomised Clinical Trials

被引:0
作者
Sven C. van Dijkman
Arzu Yorgancıoğlu
Ian Pavord
Guy Brusselle
Paulo M. Pitrez
Sean Oosterholt
Sourabh Fumali
Anurita Majumdar
Oscar Della Pasqua
机构
[1] GSK,Clinical Pharmacology Modelling and Simulation
[2] Celal Bayar University,Nuffield Department of Medicine
[3] University of Oxford,Clinical Pharmacology & Therapeutics Group
[4] Ghent University Hospital,undefined
[5] Hospital Santa Casa de Porto Alegre,undefined
[6] GSK,undefined
[7] Global Classic and Established Medicines,undefined
[8] GSK,undefined
[9] Global Classic and Established Medicines,undefined
[10] University College London,undefined
[11] GSK House,undefined
来源
Advances in Therapy | 2024年 / 41卷
关键词
Asthma symptom control; Reliever medication; Rescue medication; Short-acting beta agonists; SABA; Inhaled corticosteroids; Drug-disease modelling; Exacerbation; ICS/LABA combination therapy;
D O I
暂无
中图分类号
学科分类号
摘要
In this study, we tried to understand how patients with moderate to severe asthma use their quick-relief inhalers (like albuterol), how it relates to their symptoms and the risk of having asthma attacks. To evaluate whether differences in reliever inhaler use between patients are associated with factors like smoking or their asthma symptoms at the beginning of treatment, we gathered data from five clinical studies (n = 6212 patients). These data allowed us to create a model that predicts how often patients use their reliever inhalers (expressed as number of puffs in 24 h) during maintenance therapy with inhaled corticosteroids alone or in combination with long-acting beta agonists. The final model showed that reliever inhaler use is higher in patients who have been diagnosed with asthma for > 10 years, are smokers, have higher asthma symptom scores, and are obese or extremely obese. Patients who had asthma attacks also used their reliever inhalers more often. In addition, to understand how relief inhalers are used in real-life situations, we also created heatmaps that include a wide range of patient characteristics. By using individual patient data together with this model, we have learned that smoking, asthma control, BMI, long history of asthma and previous asthma attacks significantly influence reliever use. This information can help physicians and healthcare professionals understand know how well someone’s asthma is managed. A patient who uses their reliever inhaler often is likely not to have their asthma well controlled by their regular medications.
引用
收藏
页码:1201 / 1225
页数:24
相关论文
共 252 条
[31]  
Pavord ID(2006)Prediction of headache response in migraine treatment Cephalalgia 28 1585-28
[32]  
Brusselle G(2008)Prediction of attack frequency in migraine treatment Cephalalgia 42 301-1061
[33]  
Yorgancıoğlu A(2008)Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model J Psychiatr Res 86 521-undefined
[34]  
Pitrez PM(2020)Model-based meta-analysis of individual International Prostate Symptom Score trajectories in patients with benign prostatic hyperplasia with moderate or severe symptoms Br J Clin Pharmacol 18 31-undefined
[35]  
Pg A(2009)Measures of asthma control and quality of life: longitudinal data provide practical insights into their relative usefulness in different research contexts Qual Life Res 42 95-undefined
[36]  
Teli C(2020)New perspectives in bronchial asthma: pathological, immunological alterations, biological targets, and pharmacotherapy Immunopharmacol Immunotoxicol 28 66-undefined
[37]  
Della PO(2018)Exercise-induced bronchoconstriction: prevalence, pathophysiology, patient impact, diagnosis and management NPJ Prim Care Respir Med 8 379-undefined
[38]  
Pfeffer P(2020)Asthma: a loss of post-natal homeostatic control of airways smooth muscle with regression toward a pre-natal state Front Pediatr 5 2101402-undefined
[39]  
Hajmohammadi H(2012)In vitro effects of β-2 agonists on skeletal muscle differentiation, hypertrophy, and atrophy World Allergy Organ J 26 2103107-undefined
[40]  
Cole J(2015)Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol Eur J Intern Med 59 21-undefined